Illumina makes the DNA sequencing machines and consumables that decode genomes, acting as the 'Intel inside' for genetic research and clinical diagnostics worldwide. Their tools are the standard for reading the blueprint of life.
Money comes from selling sequencing instruments plus high-margin recurring consumables and services, with gross margins around 67% and net margins near 18% on USD 4.34B annual revenue. The consumables model drives repeat purchases after each machine sale.
Illumina's installed base and proprietary chemistry create switching costs, but Pacific Biosciences and Oxford Nanopore are eroding their dominance with cheaper long-read and portable sequencing alternatives. Moat is eroding as these competitors gain traction
Buy (sector percentile 77) — value B-, growth C, profitability B+, momentum A-, revisions B+. Updated daily, sector-relative, identical for every user.
Key events, in time order
Q2 revenue beat and guidance raised; CEO highlights strong clinical business on CNBC, yet stock remains under pressure
Fishbone Advisors report flags credibility problem with healthcare AI narrative among institutional investors
SEC 13F filing shows 18.6% trim in quarter, holding reduced to 721,532 shares
Partners to leverage unprecedented data scale for advancing precise medicines to approval
Two independent sources confirm the same analyst action, indicating institutional optimism
Rest of World（除中国外）有机增长3.5%，主要由测序耗材和仪器驱动，其中临床测序耗材增长约20%。
None yet
None yet
Illumina is included in a stock scan based on the Minervini Trend Template, indicating a potential technical breakout or upward momentum.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
